MAPRx in Action

In December 2025, the Centers for Medicare & Medicaid Services (CMS) announced two major initiatives to expand access to obesity management medications for Medicare and Medicaid beneficiaries: the Medicare GLP-1 Bridge program and the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model. CMS has announced an indefinite delay of the...

Enacted in 2022, the Inflation Reduction Act (IRA) introduced significant reforms aimed at reducing the financial burden of prescription drug costs for Medicare Part D beneficiaries.

A new report from MAPRx, however, shows that as a larger share of liability has shifted from the federal government to plans and...

The MAPRx coalition has championed policies in Part D that improve the affordability of medications and beneficiary access to those medications, including provisions of the Inflation Reduction Act (IRA) that establish an out-of-pocket cap in Part D and the Medicare Prescription Payment Plan. MAPRx strongly opposes the GUARD Model and urges CMS to...

The Medicare prescription drug benefit (Medicare Part D) has been an enormous help to beneficiaries and a policy success story by providing coverage for prescription drugs. The program filled a major gap in Medicare’s benefits and has done so with consistently high satisfaction among beneficiaries. However, for the MPPP to have a greater...

Medicare Part D prescription drug plans will have an out-of-pocket maximum of $2,100 for 2026 and beneficiaries can also opt in to the Medicare Prescription Payment Plan (MPPP)—a new program that lets you pay for prescriptions in monthly installments. The MAPRx Coalition has created this patient guide with more information.

MAPRx strongly supports CMS’ proposal to permit coverage of anti-obesity medications to treat obesity for appropriate indications. AOMs are a critical component of the continuum of obesity care. Read our Comment Letter

...